Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: Anxiety, obsessive-compulsive, and stress-related disorders frequently co-occur, and patients often present symptoms of several domains. Treatment involves the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), but data on comparative efficacy and acceptability are lacking. We aimed to compare the efficacy of SSRIs, SNRIs, and placebo in multiple symptom domains in patients with these diagnoses over the lifespan through a 3-level network meta-analysis. Methods and findings: We searched for published and unpublished randomized controlled trials that aimed to assess the efficacy of SSRIs or SNRIs in participants (adults and children) with diagnosis of any anxiety, obsessive-compulsive, or stress-related disorder in MEDLINE, PsycINFO, Embase, and Cochrane Library from inception to 23 April 2015, with an update on 11 November 2020. We supplemented electronic database searches with manual searches for published and unpublished randomized controlled trials registered in publicly accessible clinical trial registries and pharmaceutical companies’ databases. No restriction was made regarding comorbidities with any other mental disorder, participants’ age and sex, blinding of participants and researchers, date of publication, or study language. The primary outcome was the aggregate measure of internalizing symptoms of these disorders. Secondary outcomes included specific symptom domains and treatment discontinuation rate. We estimated standardized mean differences (SMDs) with 3-level network meta-analysis with random slopes by study for medication and assessment instrument. Risk of bias appraisal was performed using the Cochrane Collaboration’s risk of bias tool. This study was registered in PROSPERO (CRD42017069090). We analyzed 469 outcome measures from 135 studies (n = 30,245). All medications were more effective than placebo for the aggregate measure of internalizing symptoms (SMD −0.56, 95% CI −0.62 to −0.51, p < 0.001), for all symptom domains, and in patients from all diagnostic categories. We also found significant results when restricting to the most used assessment instrument for each diagnosis; nevertheless, this restriction led to exclusion of 72.71% of outcome measures. Pairwise comparisons revealed only small differences between medications in efficacy and acceptability. Limitations include the moderate heterogeneity found in most outcomes and the moderate risk of bias identified in most of the trials. Conclusions: In this study, we observed that all SSRIs and SNRIs were effective for multiple symptom domains, and in patients from all included diagnostic categories. We found minimal differences between medications concerning efficacy and acceptability. This three-level network meta-analysis contributes to an ongoing discussion about the true benefit of antidepressants with robust evidence, considering the significantly larger quantity of data and higher statistical power when compared to previous studies. The 3-level approach allowed us to properly assess the efficacy of these medications on internalizing psychopathology, avoiding potential biases related to the exclusion of information due to distinct assessment instruments, and to explore the multilevel structure of transdiagnostic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 9×
“We searched MEDLINE, PsycINFO, Embase, and Cochrane Library from inception to 23 April 2015, and updated the search on 11 November 2020, using keywords related to study design, interventions, and assessed disorders, defined after discussion with experts in this field (search terms are provided in S2 Appendix).”
MethodInfluentialVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Estimating effect sizes from pretest-posttest-control group designs
Morris, S. B. (2008) · Organizational Research Methods · doi:10.1177/1094428106291059 · Cited by 2,133
Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 2×
“Nonetheless, the imputation method followed previous recommendations for meta-analyses [18], and the assumed correlation was based on previous reports concerning mental health [17].”
MethodCipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Self-citationAlonso, J., Liu, Z., Evans-Lacko, S., Sadikova, E., Sampson, N., Chatterji, S., Abdulmalik, J., Aguilar-Gaxiola, S., Al-Hamzawi, A., Andrade, L. H., et al. (2018) · Depression and Anxiety · doi:10.1002/da.22711 · Cited by 716 · cited 1×
“While these conditions affect around 10% of the world’s population, only 10% of those affected receive appropriate treatment [3].”
BackgroundThe 52 symptoms of major depression: lack of content overlap among seven common depression scales
Fried, E. I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.019 · Cited by 649 · cited 2×
“Fourth, there is uncertainty about the most appropriate instruments to measure treatment gains due to the highly inconsistent and heterogeneous assessment landscape [11,12].”
BackgroundEfficacy of treatments for anxiety disorders: a meta-analysis
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000078 · Cited by 555 · cited 1×
“Bandelow and colleagues [38] also assessed the efficacy of antidepressants for anxiety disorders, including not only generalized anxiety disorder but also social anxiety disorder and panic disorder.”
BackgroundFixed effects and variance components estimation in three-level meta-analysis
Konstantopoulos, S. (2011) · Research Synthesis Methods · doi:10.1002/jrsm.35 · Cited by 521
Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt, M. E., Bloch, M. H., & Mathews, C. A. (2017) · JAMA · doi:10.1001/jama.2017.2200 · Cited by 493 · cited 1×
“Moreover, for RCTs designed to evaluate patients diagnosed with OCD, we performed a sensitivity analysis excluding studies that included participants diagnosed with tic-related OCD, hoarding, repetitive behaviors of autism, or Tourette syndrome, given that these conditions are associated with lack of pharmacological r…”
MethodLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1×
“All included SSRIs and SNRIs showed greater reduction in overall psychopathology than placebo, with effect sizes comparable to those of other interventions in medicine [29].”
ResultPre-post effect sizes should be avoided in meta-analyses
Cuijpers, P., Weitz, E., Cristea, I. A., & Twisk, J. (2017) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000809 · Cited by 432
Self-citationPsychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis
Cuijpers, P., Karyotaki, E., Eckshtain, D., Ng, M. Y., Corteselli, K. A., Noma, H., Quero, S., & Weisz, J. R. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0164 · Cited by 429
Self-citationHayasaka, Y., Purgato, M., Magni, L. R., Ogawa, Y., Takeshima, N., Cipriani, A., Barbui, C., Leucht, S., & Furukawa, T. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.021 · Cited by 401 · cited 1×
“Univariate and multiple meta-regression models considered the following variables: medication, comparator, equivalent dose (estimated using fluoxetine equivalents based on previous studies) [27], time to outcome measure, main diagnosis, sampling, sample age, publication year, benzodiazepine use, placebo lead-in, analy…”
MethodSlee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
A comparison of the utility of dimensional and categorical representations of psychosis
VAN OS, J., GILVARRY, C., BALE, R., VAN HORN, E., TATTAN, T., WHITE, I., & MURRAY ON BEHALF OF THE UK700 GROUP, R. (1999) · Psychological Medicine · doi:10.1017/s0033291798008162 · Cited by 261 · cited 1×
“Moreover, our findings provide support for transdiagnostic systems of psychopathology, which emphasize that psychosocial impairment is better explained and predicted by transdiagnostic dimensions than traditional diagnoses [31,32].”
BackgroundFurukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214
Network meta-analyses should be the highest level of evidence in treatment guidelines
Leucht, S., Chaimani, A., Cipriani, A. S., Davis, J. M., Furukawa, T. A., & Salanti, G. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0715-4 · Cited by 202 · cited 1×
“Publication of network meta-analyses in the psychiatry field is significantly increasing [8] as these analyses have been recognized as the highest level of evidence in treatment guidelines [33].”
BackgroundPharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: A systematic review
Konnopka, A., Leichsenring, F., Leibing, E., & König, H.-H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.07.014 · Cited by 161 · cited 1×
“Costs associated with these disorders account for approximately 33% of mental-health-related expenditures, particularly those related to loss of productivity [4].”
BackgroundMunkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024886 · Cited by 151 · cited 2×
“Controversy concerning antidepressants in the treatment of mood disorders [5,6] obscures vital questions for the treatment of other conditions, such as anxiety, obsessive-compulsive, and stress-related disorders.”
BackgroundRoest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101 · cited 1×
“First, there is still debate on their efficacy and acceptability [9].”
Background
Cited by
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Transdiagnostic treatment of depression and anxiety: a meta-analysis
Cuijpers, P., Miguel, C., Ciharova, M., Ebert, D., Harrer, M., & Karyotaki, E. (2023) · Psychological Medicine · doi:10.1017/s0033291722003841 · Cited by 96
“In addition, several pharmacological treatments have also been found to be effective in both depression and anxiety disorders (Cipriani et al., 2018; Gosmann et al., 2021).”
BackgroundSelf-citationGosmann, N. P., Costa, M. D. A., Jaeger, M. D. B., Frozi, J., Spanemberg, L., Manfro, G. G., Cortese, S., Cuijpers, P., Pine, D. S., & Salum, G. A. (2023) · Psychological Medicine · doi:10.1017/s0033291723001630 · Cited by 28
“We also estimated p scores for efficacy using the multiple meta-regression model of our previous work on this network meta-analysis, which evaluated the improvement of internalizing symptoms accounting for the same moderators (Gosmann et al., 2021).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Gosmann, N. P., Costa, M. D. A., Jaeger, M. D. B., Motta, L. S., Frozi, J., Spanemberg, L., Manfro, G. G., Cuijpers, P., Pine, D. S., & Salum, G. A.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-10
- Volume
- 18
- Issue
- 6
- Pages
- e1003664
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W3172784626
- Cited by
- 85
- References
- 25
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.